Jade Biosciences, a Vancouver, BC, Canada-based biotechnology company dedicated to developing therapies for patients living with autoimmune diseases, extended its financing, bringing the total raised to $95M.
The round added Frazier Life Sciences and Versant Ventures to an investor syndicate that included Fairmount, Venrock Healthcare Capital Partners, Deep Track Capital, Driehaus Capital Management, Franklin Templeton, RTW Investments, and Braidwell LP.
The company intends to use the funds to expand operations and its R&D sector.
Jade Biosciences is developing therapies with the goal of redefining the standard of care for autoimmune diseases.
Jade has also announced a newly formed Board of Directors led by Board Chairman Eric Dobmeier, former President and CEO of Chinook Therapeutics. The board includes:
- Chris Cain, Ph.D. – Director of Research, Fairmount Funds Management LLC
- Eric Dobmeier – Board Chairman, Venture Partner, Samsara BioCapital
- Tom Frohlich – CEO, Jade Biosciences
- Tomas Kiselak – Managing Member, Fairmount Funds Management LLC
- Lawrence Klein, Ph.D. – CEO of Oruka Therapeutics
- Erin Lavelle – Former COO and CFO at Profound Bio, Eliem Therapeutics; additional leadership roles at Alder BioPharmaceuticals and Amgen
FinSMEs
24/10/2024